CORDIS
EU research results

CORDIS

English EN

Preventing community and nosocomial spread and infection with MRSA ST 398 - instruments for accelerated control and integrated risk management of antimicrobial resistance

Project information

Grant agreement ID: 223050

Status

Closed project

  • Start date

    1 January 2009

  • End date

    31 December 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 727 953

  • EU contribution

    € 2 993 824

Coordinated by:

THE ROYAL VETERINARY COLLEGE

United Kingdom

Objective

Methicillin-resistant Staphylococcus aureus (MRSA) are of increasing concern both as community- and hospital-acquired pathogens. Since 2005, a specific clone, MRSA ST398 is spreading both in livestock populations and occupationally-exposed people resulting in human infection and disease in several EU Member States. The key objective of the PILGRIM project is to provide a range of novel control measures for the accelerated identification and control of emerging resistant bacteria. In order to achieve these we will undertake epidemiological and physiological studies of MRSA ST398 and use molecular approaches in well comparable animal models as well as humans in community and healthcare settings to 1) investigate/explore its biology and ecology, 2) identify and characterise factors determining the transmission pathways and risk from animal to human and between humans, 3) establish genetic differences, host-range and virulence of adhesive and non-adhesive strains as well as differences between ST398 and other MRSA, 3) identify specific genes for the development of new rapid tests to identify specific MRSA strains, 4) provide a Technology Testing Platform for developing and assessing decolonisation and environmental sanitation approaches, 5) integrate results in policy and practice guidelines. This project brings together clinical, genetic, microbiological and public health partners from 6 European countries, internationally renowned for their expertise in complementary ecosystems research. The two SME partners ensure the exploitation of results and the knowledge transfer, enabling associated companies to bring validated solutions to the market. The PILGRIM research will facilitate rapid and cost-effective measures to combat emerging resistant strains in order to prevent and eradicate community and nosocomial infections for better protection of citizens and patients in Europe and beyond.

Coordinator

THE ROYAL VETERINARY COLLEGE

Address

Royal College Street
Nw1 Otu London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 559 448

Administrative Contact

Katharina Stärk (Prof.)

Participants (11)

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 297 408

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 497 585

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 402 814

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 137 204

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom

EU Contribution

€ 451 000

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

Netherlands

EU Contribution

€ 85 896

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 194 359

VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE

Czechia

EU Contribution

€ 67 800

CENTRUM VOOR ONDERZOEK IN DIERGENEESKUNDE EN AGROCHEMIE - CODA

Belgium

EU Contribution

€ 82 780

AGUACURE LIMITED

United Kingdom

EU Contribution

€ 73 950

ACCELOPMENT AG

Switzerland

EU Contribution

€ 143 580

Project information

Grant agreement ID: 223050

Status

Closed project

  • Start date

    1 January 2009

  • End date

    31 December 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 727 953

  • EU contribution

    € 2 993 824

Coordinated by:

THE ROYAL VETERINARY COLLEGE

United Kingdom